144 related articles for article (PubMed ID: 36318027)
1. MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials.
Nedrud MA; Chaudhry M; Middleton MS; Moylan CA; Lerebours R; Luo S; Farjat A; Guy C; Loomba R; Abdelmalek MF; Sirlin CB; Bashir MR
Radiology; 2023 Mar; 306(3):e220743. PubMed ID: 36318027
[TBL] [Abstract][Full Text] [Related]
2. Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.
Jiang H; Chen HC; Lafata KJ; Bashir MR
Radiology; 2021 Aug; 300(2):361-368. PubMed ID: 34060937
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
[TBL] [Abstract][Full Text] [Related]
4. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
Stine JG; Munaganuru N; Barnard A; Wang JL; Kaulback K; Argo CK; Singh S; Fowler KJ; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2274-2283.e5. PubMed ID: 32882428
[TBL] [Abstract][Full Text] [Related]
5. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
[TBL] [Abstract][Full Text] [Related]
6. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
8. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
[TBL] [Abstract][Full Text] [Related]
9. MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis.
Hong CW; Mamidipalli A; Hooker JC; Hamilton G; Wolfson T; Chen DH; Fazeli Dehkordy S; Middleton MS; Reeder SB; Loomba R; Sirlin CB
J Magn Reson Imaging; 2018 Apr; 47(4):995-1002. PubMed ID: 28851124
[TBL] [Abstract][Full Text] [Related]
10. Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis.
Hooker JC; Hamilton G; Park CC; Liao S; Wolfson T; Dehkordy SF; Hong CW; Mamidipalli A; Gamst A; Loomba R; Sirlin CB
Abdom Radiol (NY); 2019 Feb; 44(2):482-492. PubMed ID: 30128694
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents.
Goyal NP; Sawh MC; Ugalde-Nicalo P; Angeles JE; Proudfoot JA; Newton KP; Middleton MS; Sirlin CB; Schwimmer JB
J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):99-105. PubMed ID: 31633654
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks.
Han A; Byra M; Heba E; Andre MP; Erdman JW; Loomba R; Sirlin CB; O'Brien WD
Radiology; 2020 May; 295(2):342-350. PubMed ID: 32096706
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
Tamaki N; Munaganuru N; Jung J; Yonan AQ; Loomba RR; Bettencourt R; Ajmera V; Valasek MA; Behling C; Sirlin CB; Loomba R
Gut; 2022 May; 71(5):983-990. PubMed ID: 33883248
[TBL] [Abstract][Full Text] [Related]
14. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.
Patel J; Bettencourt R; Cui J; Salotti J; Hooker J; Bhatt A; Hernandez C; Nguyen P; Aryafar H; Valasek M; Haufe W; Hooker C; Richards L; Sirlin CB; Loomba R
Therap Adv Gastroenterol; 2016 Sep; 9(5):692-701. PubMed ID: 27582882
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C).
Mamidipalli A; Fowler KJ; Hamilton G; Wolfson T; Covarrubias Y; Tran C; Fazeli S; Wiens CN; McMillan A; Artz NS; Funk LM; Campos GM; Greenberg JA; Gamst A; Middleton MS; Schwimmer JB; Reeder SB; Sirlin CB
Eur Radiol; 2020 Sep; 30(9):5120-5129. PubMed ID: 32318847
[TBL] [Abstract][Full Text] [Related]
16. Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk.
Xia T; Du M; Li H; Wang Y; Zha J; Wu T; Ju S
Radiology; 2023 Oct; 309(1):e231007. PubMed ID: 37874242
[TBL] [Abstract][Full Text] [Related]
17. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
18. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
[TBL] [Abstract][Full Text] [Related]
19. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis.
Dennis A; Kelly MD; Fernandes C; Mouchti S; Fallowfield JA; Hirschfield G; Pavlides M; Harrison S; Chakravarthy MV; Banerjee R; Sanyal A
Front Endocrinol (Lausanne); 2020; 11():575843. PubMed ID: 33584535
[TBL] [Abstract][Full Text] [Related]
20. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
Lin SC; Heba E; Bettencourt R; Lin GY; Valasek MA; Lunde O; Hamilton G; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2017 Mar; 45(6):844-854. PubMed ID: 28116801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]